Emerging Infections
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com.
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com
Emerging Infections
For any questions or information, please email: covidrapidreviewteam@gmail.com
VitaminB_AbridgedReport_29March2020_EVS_IGC
Clinical Practice Guidelines
This Clinical Practice Guideline (CPG) is intended for the use of practicing clinicians in the Philippines who are involved in the care of adult patients with sepsis and septic shock. This document may be used by government and private practicing physicians, as well as trainors and trainees with respect to medical education, training, and mentoring.
This Philippine CPG for Sepsis and Septic Shock was developed because of (1) the significant burden of disease, (2) the confusion over the definitions, (3) the significant variability in clinical practice, (4) the availability of new evidence, and (5) the feasibility issues concerning cost, availability, and access to resources in the Philippines.
Clinical Practice Guidelines
This Philippine CPG for Sepsis and Septic Shock was developed because of (1) the significant burden of disease, (2) the confusion over the definitions, (3) the significant variability in clinical practice, (4) the availability of new evidence, and (5) the feasibility issues concerning cost, availability, and access to resources in the Philippines.
The full manuscript of this CPG for Sepsis and Septic Shock can be found here.
Covid-EXTERNAL
Covid-PSMID
PSMID would like to express its strong statement against the use of CHLOROQUINE or HYDROXCHLOROQUINE should not be used for prophylaxis.
There is no high quality evidence that these will prevent COVID19. These drugs should be used cautiously because of the possible side effects.
LET’S NOT TAKE AWAY STOCKS OF CHLOROQUINE FROM THOSE WHO REALLY NEED IT!
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.
